These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
638 related articles for article (PubMed ID: 17047056)
1. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056 [TBL] [Abstract][Full Text] [Related]
2. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Kinsey M; Smith R; Lessnick SL Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343 [TBL] [Abstract][Full Text] [Related]
3. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423 [TBL] [Abstract][Full Text] [Related]
4. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. De Vito C; Riggi N; Suvà ML; Janiszewska M; Horlbeck J; Baumer K; Provero P; Stamenkovic I PLoS One; 2011; 6(8):e23592. PubMed ID: 21853155 [TBL] [Abstract][Full Text] [Related]
5. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188 [TBL] [Abstract][Full Text] [Related]
6. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082 [TBL] [Abstract][Full Text] [Related]
7. A molecular function map of Ewing's sarcoma. Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404 [TBL] [Abstract][Full Text] [Related]
8. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944 [TBL] [Abstract][Full Text] [Related]
9. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Zwerner JP; May WA Oncogene; 2001 Feb; 20(5):626-33. PubMed ID: 11313995 [TBL] [Abstract][Full Text] [Related]
11. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma. Camões MJ; Paulo P; Ribeiro FR; Barros-Silva JD; Almeida M; Costa VL; Cerveira N; Skotheim RI; Lothe RA; Henrique R; Jerónimo C; Teixeira MR PLoS One; 2012; 7(11):e49819. PubMed ID: 23185447 [TBL] [Abstract][Full Text] [Related]
12. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560 [TBL] [Abstract][Full Text] [Related]
13. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Prieur A; Tirode F; Cohen P; Delattre O Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325 [TBL] [Abstract][Full Text] [Related]
14. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
15. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Toretsky JA; Erkizan V; Levenson A; Abaan OD; Parvin JD; Cripe TP; Rice AM; Lee SB; Uren A Cancer Res; 2006 Jun; 66(11):5574-81. PubMed ID: 16740692 [TBL] [Abstract][Full Text] [Related]
16. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. González I; Vicent S; de Alava E; Lecanda F J Mol Med (Berl); 2007 Sep; 85(9):1015-29. PubMed ID: 17453169 [TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage. Ban J; Siligan C; Kreppel M; Aryee D; Kovar H Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154 [TBL] [Abstract][Full Text] [Related]
18. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Smith R; Owen LA; Trem DJ; Wong JS; Whangbo JS; Golub TR; Lessnick SL Cancer Cell; 2006 May; 9(5):405-16. PubMed ID: 16697960 [TBL] [Abstract][Full Text] [Related]
19. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047 [TBL] [Abstract][Full Text] [Related]
20. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]